Adaptimmune Therapeutics plc Stock price

Equities

ADAP

US00653A1079

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
1.47 USD -0.68% Intraday chart for Adaptimmune Therapeutics plc -4.55% +85.37%
Sales 2024 * 81.85M Sales 2025 * 73.92M Capitalization 363M
Net income 2024 * -96M Net income 2025 * -120M EV / Sales 2024 * 4.43 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 4.91 x
P/E ratio 2024 *
-12.3 x
P/E ratio 2025 *
-6.39 x
Employees 449
Yield 2024 *
-
Yield 2025 *
-
Free-Float 15.06%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading MT
ADRs Close Lower, Immuron Ltd. Declines 17.1% DJ
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading MT
ADRs Close Higher; Dada Nexus Ltd. Climbs 30% DJ
Transcript : Adaptimmune Therapeutics plc, Q4 2023 Earnings Call, Mar 06, 2024
Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (ADAP) ADAPTIMMUNE THERAPEUTICS Reports Q4 Revenue $231,000, vs. Street Est of $26M MT
Adaptimmune Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
European Equities Traded in the US as American Depositary Receipts Decline Tuesday MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
Adaptimmune Therapeutics plc Appoints Cintia Piccina as Chief Commercial Officer, Effective March 18, 2024 CI
European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5% MT
More news
1 day-0.68%
1 week-4.55%
Current month-6.37%
1 month+22.50%
3 months+227.03%
6 months+98.51%
Current year+85.37%
More quotes
1 week
1.36
Extreme 1.36
1.70
1 month
1.18
Extreme 1.18
2.05
Current year
0.65
Extreme 0.6517
2.05
1 year
0.42
Extreme 0.42
2.05
3 years
0.42
Extreme 0.42
6.86
5 years
0.42
Extreme 0.42
13.40
10 years
0.42
Extreme 0.42
21.57
More quotes
Managers TitleAgeSince
Founder 57 07-12-31
Chief Executive Officer 52 15-02-28
Director of Finance/CFO 54 20-03-31
Members of the board TitleAgeSince
Director/Board Member 60 Oct. 31
Director/Board Member 57 23-05-31
Chairman 58 14-08-31
More insiders
Date Price Change Volume
24-03-18 1.47 -0.68% 1,093,143
24-03-15 1.48 +1.37% 634,191
24-03-14 1.46 -8.18% 1,339,697
24-03-13 1.59 +6.71% 1,398,467
24-03-12 1.49 -3.25% 1,624,048

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and has reported responses in multiple solid tumor indications. Its platform helps to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include genetically engineered T-cell receptors (TCRs) and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its MAGE-A4 cell therapy franchise includes T-cell therapy products targeting solid tumor indications in which the MAGE-A4 antigen is expressed, with responses seen in eight indications (head and neck, esophagogastric junction, non-small cell lung cancer-squamous, synovial sarcoma, melanoma, urothelial, ovarian and myxoid/round cell liposarcoma indications).
Calendar
2024-04-17 - Investor Day
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.47 USD
Average target price
3.6 USD
Spread / Average Target
+144.90%
Consensus
  1. Stock
  2. Equities
  3. Stock Adaptimmune Therapeutics plc - Nasdaq